Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Non-small cell lung cancer (NSCLC)

Lactate dehydrogenase A
(LDHA); K-Ras (KRAS); epidermal growth factor receptor 1 (EGFR1; HER1; ErbB1)

Mouse studies suggest inhibiting LDHA could help treat KRAS- and EGFR1-mutant NSCLC. LDHA catalyzes a key step in anaerobic glycolysis, which NSCLC relies upon for growth and metastasis. In normal mice, injection of a human KRAS-mutant NSCLC cell line expressing an LDHA shRNA resulted in fewer metastatic lesions than injection of unmodified cells. In mice with NSCLC xenograft tumors harboring activating mutations in KRAS or EGFR1, Ldha deficiency decreased glycolytic metabolite levels and tumor growth compared with unmodified Ldha expression. Results of Ldha deficiency in other tumor types will be reported in an upcoming publication.

SciBX 7(17); doi:10.1038/scibx.2014.492
Published online May 1, 2014

Unpatented; licensing status not applicable

Xie, H. et al. Cell Metab.; published online April 10, 2014;
doi:10.1016/j.cmet.2014.03.003
Contact: Pankaj Seth, Beth Israel Deaconess Medical Center, Boston, Mass.
e-mail:

pseth@bidmc.harvard.edu
Contact: Teresa W.M. Fan, University of Louisville, Louisville, Ky.
e-mail:

teresa.fan@uky.edu